BG Medicine Announces Data Analyses Presented at American Heart Association Meeting

BG Medicine Announces Data Analyses Presented at American Heart Association
Meeting

WALTHAM, Mass., Nov. 9, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD), a company focused on the development and commercialization of
novel cardiovascular diagnostics, today announced that results of
retrospective analyses of the BioImage Study cohort were presented this week
at the American Heart Association (AHA) Scientific Sessions 2012 in Los
Angeles. These presentations resulted from research sponsored by the company
and included data on the CardioSCORE™ test, a proprietary blood test currently
being developed by the company.

In four scientific presentations, investigators from the Mt. Sinai School of
Medicine and the Baptist Hospital of Miami jointly presented the following
findings:

  "BioImage Study: Value of Novel Biomarker Panel (CardioSCORE) in Predicting
  Major Adverse Cardiovascular Events among those with Absence of Coronary
  Calcification" assessed the value of the CardioSCORE test for predicting
  near-term cardiovascular risk among the 1,832 study participants who were
  found to be free of coronary arterial calcification as determined by
  computed tomography. For this group, otherwise assessed to be at low risk
  for cardiovascular events, investigators reported that elevated CardioSCORE
  test results were associated with a significantly increased risk of major
  cardiovascular events, including heart attack and ischemic stroke, in the
  near-term follow-up period of 2.5 years.

  "BioImage Study: Reclassification and Discrimination by Novel Biomarker
  Panel (CardioSCORE), Coronary Calcium Score, Carotid Intima-Media Thickness
  & Plaque Burden in Asymptomatic Individuals" compared the predictive power
  of the CardioSCORE test to three atherosclerosis imaging modalities
  including coronary artery calcium evaluation by computed tomography,
  ultrasound carotid intima-media thickness assessment, and ultrasound carotid
  atherosclerotic plaque quantification. Across the entire study cohort,
  investigators reported that the CardioSCORE test yielded near-term
  cardiovascular event prediction significantly better than conventional
  ultrasound imaging methodologies, and was of comparable predictive power as
  coronary artery calcium evaluation.

  "BioImage Study: Novel Biomarker Panel (CardioSCORE) for the Prediction of
  First Major Cardiovascular Events across the Full Range of Framingham Risk
  Scores" assessed the extent of the additive predictive value of the
  CardioSCORE test to traditional risk factor scoring as aggregated in the
  Framingham Risk Score, in 6,600 study participants. Investigators reported
  that the addition of the CardioSCORE test to the Framingham Risk Score
  significantly increased the accuracy with which individuals at high risk for
  near-term events were correctly identified, particularly within the low and
  intermediate risk categories.

  "BioImage Study: Combined Use of Novel Biomarker Panel (CardioSCORE) and
  Computed Tomography Coronary Calcium Scores in Predicting Major Adverse
  Cardiovascular Events" assessed 5,763 study participants to determine the
  extent of the additive predictive value of the CardioSCORE Test to coronary
  artery calcium scoring by computed tomography. Investigators reported that
  the addition of CardioSCORE test results to coronary artery calcium scoring
  significantly increased the accuracy with which individuals at high risk for
  near-term events were correctly identified across all levels of coronary
  calcification.

"These results suggest that the CardioSCORE test has the significant potential
to provide valuable information about an individual's risk of experiencing a
near-term heart attack or stroke," said Eric Bouvier, President and CEO of BG
Medicine. "There is a critical need for a simple and easy-to-use blood test to
more accurately determine a patient's risk for these types of catastrophic
events."

About The CardioSCORE™ Test

The CardioSCORE test is a proprietary blood test that measures the levels of
several protein biomarkers and integrates the results to yield a single
numerical score that is related to an individual's risk for near-term major
cardiovascular events. The CardioSCORE test is not yet commercially available
and is currently under development in the United States.

About the BioImage Study

The ongoing BioImage study is a prospective, epidemiological study comprising
more than 7,000 community-dwelling individuals. It was designed to investigate
the relationship between imaging and blood biomarkers and major cardiovascular
event rates, in order to develop more reliable and simple means of identifying
individuals before their first major event.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the
discovery, development and commercialization of novel cardiovascular
diagnostics to address significant unmet medical needs, improve patient
outcomes and reduce healthcare costs. The Company's first commercialized
product, the BGM Galectin-3^® test for use in patients with chronic heart
failure, is available in the United States and Europe. BG Medicine is also
developing the CardioSCORE ^ TM test, a blood test designed to aid in the
assessment of an individual's risk for near-term major cardiovascular
events.For additional information about BG Medicine, heart failure and
galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.

The BG Medicine Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Special Note Regarding Forward-looking Statements

Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor" created by those
sections. Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can generally be
identified by the use of forward-looking terms such as "believe," "expect,"
"may," "will," "should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms.Forward-looking statements in this
news release address our belief in the significant potential of the
CardioSCORE test to provide valuable information about an individual's risk of
experiencing near-term major cardiovascular events; our belief that there is a
critical need for a simple and easy-to-use blood test to more accurately
determine patients' risks for near-term major cardiovascular events; our
belief that the CardioSCORE test may improve the identification of individuals
at high risk for near-term major cardiovascular events over conventional risk
factor scoring; our expectations regarding the impact of the BioImage Study
cohort data on potential sales and marketing of the CardioSCORE
test.Forward-looking statements are based on management's current
expectations and involve inherent risks and uncertainties which could cause
actual results to differ materially from those in the forward-looking
statements, as a result of various factors including those risks and
uncertainties described in the Risk Factors and in Management's Discussion and
Analysis of Financial Condition and Results of Operations sections of our
recent filings with the Securities and Exchange Commission, including our most
recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.We urge
you to consider those risks and uncertainties in evaluating our
forward-looking statements.We caution readers not to place undue reliance
upon any such forward-looking statements, which speak only as of the date
made.Except as otherwise required by the federal securities laws, we disclaim
any obligation or undertaking to publicly release any updates or revisions to
any forward-looking statement contained herein (or elsewhere) to reflect any
change in our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Charles Abdalian
         EVP & Chief Financial Officer
         (781) 890-1199

BG Medicine Inc. logo